Where does Palvella Therapeutics's income statement data come from?

Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net interest income	$2.91M+12.4%	$2.59M+10.2%	$2.35M+23.1%	$1.91M+68.4%	$1.13M+142%
Research and development	$28.1M+23.0%	$22.84M+25.1%	$18.26M+22.4%	$14.92M+32.7%	$11.24M+37.9%
General and administrative	$17.49M+10.9%	$15.76M+17.6%	$13.4M+15.2%	$11.63M+29.7%	$8.97M+50.8%
Other operating expenses	$45.59M+18.1%	$38.6M+21.9%	$31.66M+19.3%	$26.55M+31.4%	$20.21M+43.4%
Total operating expenses	$45.59M+18.1%	$38.6M+21.9%	$31.66M+19.3%	$26.55M+31.4%	$20.21M+43.4%
Operating income	-$45.59M-18.1%	-$38.6M-21.9%	-$31.66M-19.3%	-$26.55M-31.4%	-$20.21M-43.4%
Other income (expense), net	——	——	$818K+7.1%	$764K+186%	$267K+521%
Income before income taxes	-$49.3M-18.2%	-$41.72M-26.6%	-$32.95M-16.1%	-$28.38M-23.0%	-$23.08M-32.4%
Income tax expense	$0—	$0—	$0—	$0—	$0—
Net income	-$49.3M-18.2%	-$41.72M-26.6%	-$32.95M-16.1%	-$28.38M-23.0%	-$23.08M-32.4%
Diluted earnings per share	-$4.17-12.4%	-$3.71-41.1%	-$2.63+52.5%	-$5.54+22.5%	-$7.15+10.1%
Basic earnings per share	-$4.17-12.4%	-$3.71-41.1%	-$2.63+52.5%	-$5.54+22.5%	-$7.15+10.1%
Weighted-average shares, diluted	46.5M+4.7%	44.4M+25.5%	35.4M+35.7%	26.1M+55.3%	16.8M+123%
Weighted-average shares, basic	46.5M+4.7%	44.4M+25.5%	35.4M+35.7%	26.1M+55.3%	16.8M+123%
Fair Value Adjustments On Derivative Liabilities Contingent Value Right Liability	——	——	——	——	-$1.48M+25.0%
Interest Income Expense Nonoperating Royalty Agreement	-$6.64M-14.2%	-$5.82M-11.8%	-$5.2M-10.5%	-$4.71M-9.6%	-$4.3M-10.5%
Other Income Expense From Research And Development Tax Credit Receivable	——	$0-100%	$494.5K-50.0%	$989K-33.3%	$1.48M-25.0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$49.2M-18.2%	-$41.64M-29.0%	-$32.27M-14.8%	-$28.11M-22.8%	-$22.89M-31.3%
Interest Income (Expense), Operating	$2.91M+12.4%	$2.59M+10.2%	$2.35M+23.1%	$1.91M+68.4%	$1.13M+142%
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax	——	——	$104K+194%	-$111K-3,600%	-$3K-200%
Other income, net (Note 6)	——	——	$818K+7.1%	$764K+186%	$267K+521%
Change in fair value of interest rate swap	-$435K-10.4%	-$394K+21.8%	-$504K-1.4%	-$497K+23.5%	-$650K-2.7%
EBIT	-$45.59M-18.1%	-$38.6M-21.9%	-$31.66M-19.3%	-$26.55M-31.4%	-$20.21M-43.4%
EBITDA	——	——	——	——	——
EBIT	-$45.59M-18.1%	-$38.6M-21.9%	-$31.66M-19.3%	-$26.55M-31.4%	-$20.21M-43.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Palvella Therapeutics's income statement data come from?: Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.